AdvaMed Announces New Board Chair and Medical Imaging Division
Peter J. Arduini, president and CEO of GE HealthCare, is the new Chair of the AdvaMed Board of Directors. Arduini has been president and CEO of GE HealthCare since January 2022. He previously served as president and CEO of Integra LifeSciences Holdings Corporation, and corporate vice president and president of Medication Delivery, Baxter Healthcare, from 2005 to 2010. In the wake of former AdvaMed Chair Ashley McEvoy’s departure from Johnson & Johnson Medtech in October, Arduini stepped in to serve as interim chair. The full Board elected him unanimously to a two-year term, which began on Friday, December 8.
“I appreciate the confidence my fellow AdvaMed Board members have placed in me as the Board’s new chair,” said Arduini. “Through Scott Whitaker’s leadership, AdvaMed has become a unifying voice for our industry to foster growth and innovative new solutions for patients, providers and health systems. The medical technology industry is at the forefront of defining the future of health care through smart devices, diagnostics and digital solutions that can enable earlier and more precise diagnoses, targeted treatments and improved patient outcomes. We need policies that keep pace with innovation, while fostering the highest ethical standards that improve patient access to the best care possible. With the promise of artificial intelligence and the interconnectivity of medical technologies, there has never been a more important time in our history to make profound and lasting changes in the delivery of care for patients.”
Last week AdvaMed also announced the establishment of a new Medical Imaging Technology division focused on advocating on behalf of large and small companies for the essential role of medical imaging technology, radiopharmaceuticals, contrast media and focused ultrasound devices in the U.S. healthcare system. Patrick Hope, former executive director of the Medical Imaging & Technology Alliance (MITA) will serve as executive director of the new Medical Imaging Technology division. “The future is brighter than ever for the medical imaging companies we served at MITA. Our new home at AdvaMed makes perfect sense: For the first time, we will be surrounded by a team, infrastructure and resources focused entirely on the patients our companies serve,” he said. “We will be surrounded by and working directly with experts in medtech policy at the state, national and global levels. I am 100% confident that our companies will see more value in our work together under the AdvaMed umbrella than ever before.”
Related Articles
-
Manufacturers preparing premarket submissions should provide performance specifications for the quantitative imaging functions, supporting performance data, and sufficient information for the end user to obtain, understand and interpret the values provided.
-
The guidance is intended to clarify the FDA’s approach for referencing the terms “device” and “counterfeit device” in FDA documents, as well as how the agency intends to interpret existing references to section 201(h) of the FD&C Act in guidance,…
-
The AHRQ brief proposes a framework to assess the risk/safety, technical functionality and mental health features of apps. The framework can be used by advocacy organizations, payers, healthcare systems and others to inform selection of mental health mobile apps.
-
The committee will advise the Commissioner of Food and Drugs on issues related to Digital Health Technologies (DHTs), and FDA policies and regulations about these technologies, providing relevant expertise and perspective to improve the FDA’s understanding of the benefits, risks…
